Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination.
BAU, binding antibody units
CAID, cirrhosis-associated immune dysfunction
COVID-19
Cirrhosis
IFN-γ, interferon-γ
LOD, limit of detection
RBD, receptor-binding domain
S1, spike 1
SARS-CoV-2
T cells response
antibody response
vaccination
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
11
01
2022
revised:
15
03
2022
accepted:
13
04
2022
pubmed:
4
5
2022
medline:
4
5
2022
entrez:
3
5
2022
Statut:
ppublish
Résumé
Cirrhosis entails elevated risk of COVID-19-associated mortality. This study determined T cell-mediated and antibody reactivity against the spike 1 (S1) protein of SARS-CoV-2 among 48 patients with cirrhosis and 39 healthy controls after mRNA COVID-19 vaccination. SARS-CoV-2-specific T-cell reactivity was measured by induced level of T cell-derived interferon-γ (IFN-γ) in blood cells stimulated T-cell reactivity against S1 was reduced in patients with cirrhosis after the 1 Patients with cirrhosis show deficient T-cell reactivity against SARS-CoV-2 antigens along with diminished levels of anti-RBD-S1 IgG after dual COVID-19 vaccination, highlighting the need for vigilance and additional preventative measures. EudraCT 2021-000349-42. T cells are a pivotal component in the defence against viruses. We show that patients with cirrhosis have impaired SARS-CoV-2-specific T-cell responses and lower antibody levels after mRNA vaccination against COVID-19 compared with healthy controls. Patients with more advanced liver disease exhibited particularly inferior vaccine responses. These results call for additional preventative measures in these patients.
Sections du résumé
Background & Aims
UNASSIGNED
Cirrhosis entails elevated risk of COVID-19-associated mortality. This study determined T cell-mediated and antibody reactivity against the spike 1 (S1) protein of SARS-CoV-2 among 48 patients with cirrhosis and 39 healthy controls after mRNA COVID-19 vaccination.
Methods
UNASSIGNED
SARS-CoV-2-specific T-cell reactivity was measured by induced level of T cell-derived interferon-γ (IFN-γ) in blood cells stimulated
Results
UNASSIGNED
T-cell reactivity against S1 was reduced in patients with cirrhosis after the 1
Conclusions
UNASSIGNED
Patients with cirrhosis show deficient T-cell reactivity against SARS-CoV-2 antigens along with diminished levels of anti-RBD-S1 IgG after dual COVID-19 vaccination, highlighting the need for vigilance and additional preventative measures.
Clinical trial registration
UNASSIGNED
EudraCT 2021-000349-42.
Lay summary
UNASSIGNED
T cells are a pivotal component in the defence against viruses. We show that patients with cirrhosis have impaired SARS-CoV-2-specific T-cell responses and lower antibody levels after mRNA vaccination against COVID-19 compared with healthy controls. Patients with more advanced liver disease exhibited particularly inferior vaccine responses. These results call for additional preventative measures in these patients.
Identifiants
pubmed: 35502229
doi: 10.1016/j.jhepr.2022.100496
pii: S2589-5559(22)00068-4
pmc: PMC9045869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100496Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Front Immunol. 2021 Jan 26;11:534731
pubmed: 33574809
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Gut. 2021 Mar;70(3):531-536
pubmed: 32660964
J Clin Transl Hepatol. 2017 Mar 28;5(1):50-58
pubmed: 28507927
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Front Immunol. 2019 Feb 25;10:293
pubmed: 30873165
Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):112-134
pubmed: 34703031
J Infect Dis. 2022 Jan 12;:
pubmed: 35022764
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
Front Immunol. 2022 Jan 19;12:798117
pubmed: 35126362
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):713-719
pubmed: 33994708
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Scand J Gastroenterol. 1989 Apr;24(3):269-76
pubmed: 2734585
EBioMedicine. 2019 Nov;49:258-268
pubmed: 31678004
J Hepatol. 2021 Dec;75(6):1434-1439
pubmed: 34454993
Viruses. 2022 Jan 21;14(2):
pubmed: 35215801
Clin Exp Hepatol. 2018 Sep;4(3):158-164
pubmed: 30324140